Pharvaris (PHVS) said the FDA accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for on-demand treatment of hereditary angioedema (Hereditary Angio...). The acceptance is a positive regulatory milestone, but with the full review outcome and timelines not yet specified.
Pharvaris (PHVS) said the FDA accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for on-demand treatment of hereditary angioedema (Hereditary Angio...). The acceptance is a positive regulatory milestone, but with the full review outcome and timelines not yet specified.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
